Editas Medicine Inc. (NASDAQ:EDIT)’s share price dropped 2.2% on Wednesday . The company traded as low as $14.36 and last traded at $14.57, with a volume of 127,760 shares traded. The stock had previously closed at $14.90.

EDIT has been the topic of a number of research reports. Zacks Investment Research downgraded shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Tuesday, May 24th. Jefferies Group initiated coverage on shares of Editas Medicine in a research note on Thursday, June 2nd. They issued a “hold” rating and a $35.00 price target on the stock. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $33.50.

The firm’s market capitalization is $528.94 million. The stock has a 50 day moving average price of $18.77 and a 200 day moving average price of $28.49.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/editas-medicine-inc-edit-trading-down-2-2.html

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.54) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.54). On average, equities analysts anticipate that Editas Medicine Inc. will post ($2.59) EPS for the current fiscal year.

In related news, major shareholder Polaris Venture Management Co. sold 500,000 shares of the company’s stock in a transaction dated Thursday, September 8th. The shares were sold at an average price of $16.80, for a total value of $8,400,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Kevin P. Starr sold 5,890 shares of the company’s stock in a transaction dated Tuesday, September 6th. The stock was sold at an average price of $15.90, for a total transaction of $93,651.00. The disclosure for this sale can be found here.

A number of institutional investors have recently made changes to their positions in the company. Nationwide Fund Advisors purchased a new position in shares of Editas Medicine during the second quarter worth about $115,000. Royal Bank of Canada acquired a new position in shares of Editas Medicine during the first quarter worth $164,000. Metropolitan Life Insurance Co. NY acquired a new position in shares of Editas Medicine during the second quarter worth $181,000. BlackRock Advisors LLC raised its position in shares of Editas Medicine by 175.4% in the second quarter. BlackRock Advisors LLC now owns 8,827 shares of the company’s stock worth $215,000 after buying an additional 5,622 shares during the period. Finally, Swiss National Bank acquired a new position in shares of Editas Medicine during the second quarter worth $242,000. Institutional investors own 61.00% of the company’s stock.

About Editas Medicine

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

5 Day Chart for NASDAQ:EDIT

Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.